|
|
| (16 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| Beta-Lactams
| | #REDIRECT[[Antibiotics (Main)]] |
| | |
| * Penicillin
| |
| * Strep Pharyngitis (including scarlet fever)Streptococcal Toxic Shock and Necrotizing Fascitis
| |
| | |
| | |
| * Penicillin plus clindamycin (to decrease toxin synthesis)
| |
| * Meningococcus Meningitis
| |
| * Syphilis (Primary, 2ndary, and latent syphilis < 1 year duration)
| |
| * Actinomycosis
| |
| * Anthrax
| |
| * Clostridial infections
| |
| * Listeria
| |
| * Pasteurella
| |
| * Penicilinase-Resistant Penicillins
| |
| * Nafcillin, oxacillin, dicloxacillin
| |
| * Agents of 1st choice for treatment of S. aureus and S. epidermidis that are not methicillin-reistant
| |
| * Expanded-Spectrum Penicillins
| |
| * Ampicillin, amoxicillin (+ clavulanate)
| |
| * Upper Respiratory Infections (due to S. pyogenes, S. pneumoniae, H. influenzae)
| |
| * Sinusitis
| |
| * Otitis media
| |
| * Acute exacerbation of chronic bronchitis
| |
| * Listeria
| |
| * Antipseudomonal Penicillins
| |
| * Piperacillin
| |
| * Infection following burns
| |
| * Neutropenia
| |
| * 1st Gen Cephalosporins
| |
| * Cefazolin, cephalexin
| |
| * Skin and soft tissue infections (why is agent of choice before gen sx)
| |
| * Cross-reactivity of PCN allergy 7% to 18%
| |
| * 2nd Gen Cephalosporins
| |
| * Cefuroxime
| |
| * Intestinal anaerobes (why is agent of chioce for colorectal sx)
| |
| * Largely displaced by 3rd gen agents
| |
| * 3rd Gen Cephalosporins
| |
| * Ceftriaxone, Ceftazidime, Cefixime
| |
| * Drug of choice for serious infections due to:
| |
| * Klebsiella
| |
| * Enterobacter
| |
| * Proteus
| |
| * Haemophilus
| |
| * Gonorrhea
| |
| * Lyme disease
| |
| * Meningitis (+ vanc and ampicillin)
| |
| * Pseudomonas meningitis (+ AG)
| |
| * 4th Gen Cephalosporins
| |
| * Cefepime
| |
| * Resistant, nosocomial infections
| |
| * Carbapenems
| |
| * Imipenem (+ cilastatin), meropenem
| |
| * Cephalosporin-resistant nosocomial bacteria
| |
| * Empirical treatment of serious infections in patients who recently received other b-lactams
| |
| * Aztreonam
| |
| * Antimicrobial activity more closely resembles AGs (only active against gram -)
| |
| * Enterobacter, pseudomonas, H. influenzae, gonococci
| |
| * Little allergic cross-reactivity with B-lactam antibiotics
| |
|
| |
| | |
| Aminoglycosides
| |
| | |
| * Gentamicin, amikacin, streptomycin (either alone or with B-lactam)
| |
| * Serious gram-negative bacillary infections
| |
| * Ill patient with pyelonephritis
| |
| * Meningitis (due to Pseudomonas, Acinetobacter)
| |
| * Peritoneal Dialysis–Associated Peritonitis
| |
| * Bacterial endocarditis?
| |
| * Caution: Use in patients with Myasthenia Gravis, can precipitate crisis
| |
| | |
| | |
|
| |
| | |
| Sulfonamides
| |
| | |
| * Trimethoprim-sulfamethoxazole
| |
| * 1st line for uncomplicated lower UTI (especially chronic and recurrent infections)
| |
| * PCP pneumonia
| |
| * Acute exacerbations of chronic bronchitis
| |
| * Maxillary sinusitis
| |
|
| |
| | |
| Fluoroquinolones
| |
| | |
| * UTI (2nd line)
| |
| * Prostatitis
| |
| * Chlamydia
| |
| * PID
| |
| * Traveler's diarrhea
| |
|
| |
| | |
| Tetracyclines
| |
| | |
| * Mycoplasma
| |
| * Chlamydia
| |
| * PID (combined with cephalosporin)
| |
| * Epididymitis
| |
| * Anthrax
| |
|
| |
| | |
| Macrolides
| |
| | |
| * Erythromycin, Clarithromycin, Azithromycin
| |
| * Community-acquired PNA
| |
| * Mycoplasma
| |
| * Legionnaires' Disease
| |
| * Chlamydia (single dose)
| |
| * H. Pylori
| |
| * Traveler's diarrhea (children and pregnant women)
| |
|
| |
| | |
| Clindamycin
| |
| | |
| * Drug of choice for lung abscess and anaerobic lung and pleural space infections
| |
| * Toxin-mediated disease, i.e. toxic shock syndrome (TSS)
| |
|
| |
| | |
| Source: Goodman & Gilman's Pharmacology
| |
| | |
| | |
| | |
| | |
| [[Category:ID]]
| |
